In light of the growing epidemics of nonalcoholic fatty liver disease (NAFLD), identification and validation of the novel biochemical surrogate markers for nonalcoholic steatohepatitis (NASH) are paramount to reduce the necessity for liver biopsy. The availability of such markers has tremendous potential to radically alter the management strategies of NAFLD patients and to monitor the disease activity. Although current biomarkers do not entirely fulfill the many requirements for the identification of patients with NASH, they should not discourage our quest, but remind us that we need to cognize the challenges ahead. (C) 2009 The WJG Press and Baishideng. All rights reserved
Assessing for the presence of non-alcoholic steatohepatitis (NASH) and the presence of advanced fibr...
BACKGROUND: Liver histology remains the gold standard for assessing non-alcoholic fatty liver diseas...
© 2017 The incidence and prevalence of nonalcoholic fatty liver disease (NAFLD) are increasing and i...
In light of the growing epidemics of nonalcoholic fatty liver disease (NAFLD), identification and va...
With the continuing epidemics of obesity and diabetes, nonalcoholic fatty liver disease (NAFLD) has ...
With the continuing epidemics of obesity and diabetes, nonalcoholic fatty liver disease (NAFLD) has ...
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the We...
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the We...
The term non-alcoholic fatty liver disease (NAFLD) comprises at least four pathological entities (de...
Nonalcoholic fatty liver disease (NAFLD) affects 25% of the global adult population and is the most ...
Non-alcoholic fatty liver disease (NAFLD) is now the most common chronic liver disease in the United...
Non-alcoholic fatty liver disease (NAFLD) is now the most common chronic liver disease in the United...
The spectrum of nonalcoholic fatty liver disease (NAFLD) includes steatosis, nonalcoholic steatohepa...
The spectrum of nonalcoholic fatty liver disease (NAFLD) includes steatosis, nonalcoholic steatohepa...
The global prevalence of nonalcoholic fatty liver disease (NAFLD) or metabolic associated fatty live...
Assessing for the presence of non-alcoholic steatohepatitis (NASH) and the presence of advanced fibr...
BACKGROUND: Liver histology remains the gold standard for assessing non-alcoholic fatty liver diseas...
© 2017 The incidence and prevalence of nonalcoholic fatty liver disease (NAFLD) are increasing and i...
In light of the growing epidemics of nonalcoholic fatty liver disease (NAFLD), identification and va...
With the continuing epidemics of obesity and diabetes, nonalcoholic fatty liver disease (NAFLD) has ...
With the continuing epidemics of obesity and diabetes, nonalcoholic fatty liver disease (NAFLD) has ...
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the We...
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the We...
The term non-alcoholic fatty liver disease (NAFLD) comprises at least four pathological entities (de...
Nonalcoholic fatty liver disease (NAFLD) affects 25% of the global adult population and is the most ...
Non-alcoholic fatty liver disease (NAFLD) is now the most common chronic liver disease in the United...
Non-alcoholic fatty liver disease (NAFLD) is now the most common chronic liver disease in the United...
The spectrum of nonalcoholic fatty liver disease (NAFLD) includes steatosis, nonalcoholic steatohepa...
The spectrum of nonalcoholic fatty liver disease (NAFLD) includes steatosis, nonalcoholic steatohepa...
The global prevalence of nonalcoholic fatty liver disease (NAFLD) or metabolic associated fatty live...
Assessing for the presence of non-alcoholic steatohepatitis (NASH) and the presence of advanced fibr...
BACKGROUND: Liver histology remains the gold standard for assessing non-alcoholic fatty liver diseas...
© 2017 The incidence and prevalence of nonalcoholic fatty liver disease (NAFLD) are increasing and i...